|
25 Companies |
|
25 Products |
|
25 Products |
|
32 Mechanisms of Action |
|
0 Trials |
|
83 News |
|
| 12» |
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion: Sitagliptin and Brown Adipose Tissue (clinicaltrials.gov) - Jul 16, 2018
P4, N=30, Completed, Sponsor: Ingrid Jazet
Recruiting --> Completed
- | saracatinib (AZD0530) / AstraZeneca
Enrollment change, Metastases: AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 3, 2018
P2, N=17, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=37 --> 17
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion, Metastases: A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Jun 12, 2018
P3, N=16, Completed, Sponsor: Xian-Janssen Pharmaceutical Ltd.
N=37 --> 17 Active, not recruiting --> Completed
- | cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Apr 20, 2018
P2, N=46, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | propranolol / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: STBETA: Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers (clinicaltrials.gov) - Jan 24, 2018
P2, N=2, Completed, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Recruiting --> Completed | N=15 --> 2 | Trial primary completion date: Apr 2017 --> Nov 2017
- | alisertib (MLN8237) / Puma
Trial completion, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Dec 19, 2017
P2, N=72, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=15 --> 2 | Trial primary completion date: Apr 2017 --> Nov 2017 Suspended --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015
- | Istodax (romidepsin) / Astellas, BMS
Trial completion, Trial initiation date, Trial primary completion date, Metastases: Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 14, 2017
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015 Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008
- rosiglitazone / Generic mfg.
Trial completion: Rosiglitazone in Treating Patients With Liposarcoma (clinicaltrials.gov) - Feb 13, 2017
P2, N=32, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008 Active, not recruiting --> Completed
- Trial completion, Enrollment change: Troglitazone in Treating Patients With Liposarcoma (clinicaltrials.gov) - Feb 13, 2017
P2, N=85, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=150 --> 85
- |||| Ibrance (palbociclib) / Pfizer
Trial completion, Trial primary completion date, Metastases: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma (clinicaltrials.gov) - Oct 27, 2016
P2, N=90, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | N=150 --> 85 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Oct 2016
- || Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma (clinicaltrials.gov) - Oct 11, 2016
P2, N=86, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Oct 2016 Trial primary completion date: Sep 2016 --> Sep 2017
- | Xiaflex (collagenase clostridium histolyticum) / Asahi Kasei, SOBI, Endo
Trial completion: Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma (clinicaltrials.gov) - Aug 26, 2016
P2, N=18, Completed, Sponsor: Gerut, Zachary, M.D.
Trial primary completion date: Sep 2016 --> Sep 2017 Active, not recruiting --> Completed
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment closed, Enrollment change, Metastases: A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Aug 2, 2016
P3, N=16, Active, not recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=141 --> 16
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 19, 2016
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=141 --> 16 Active, not recruiting --> Completed
- | Januvia (sitagliptin) / Merck (MSD)
Enrollment open, Trial initiation date, Trial primary completion date: Sitagliptin and Brown Adipose Tissue (clinicaltrials.gov) - Mar 25, 2016
P4, N=30, Recruiting, Sponsor: IngridJazet
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Mar 2014 | Trial primary completion date: May 2016 --> Aug 2016
- |||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016
P2, N=216, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Mar 2014 | Trial primary completion date: May 2016 --> Aug 2016 Active, not recruiting --> Completed
- | Xiaflex (collagenase clostridium histolyticum) / Asahi Kasei, SOBI, Endo
Enrollment closed, Trial primary completion date: Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma (clinicaltrials.gov) - Feb 11, 2016
P2, N=18, Active, not recruiting, Sponsor: Gerut, Zachary, M.D.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Apr 2016
- alisertib (MLN8237) / Puma
Enrollment change, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Feb 3, 2016
P2, N=72, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Apr 2016 N=135 --> 72
- cyclophosphamide / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Metastases: NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (clinicaltrials.gov) - Feb 3, 2016
P1, N=0, Withdrawn, Sponsor: Fred Hutchinson Cancer Research Center
N=135 --> 72 N=12 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Jan 2016
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma (clinicaltrials.gov) - Dec 10, 2015
P2, N=42, Active, not recruiting, Sponsor: Vector Oncology
N=12 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Jan 2016 Trial primary completion date: Jun 2014 --> Oct 2015
- alisertib (MLN8237) / Puma
Enrollment change, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 7, 2015
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Oct 2015 N=59 --> 135 | Trial primary completion date: Aug 2015 --> Feb 2016
- alisertib (MLN8237) / Puma
Enrollment change, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Sep 16, 2015
P2, N=59, Suspended, Sponsor: National Cancer Institute (NCI)
N=59 --> 135 | Trial primary completion date: Aug 2015 --> Feb 2016 N=135 --> 59 | Trial primary completion date: Feb 2016 --> Aug 2015
- alisertib (MLN8237) / Puma
Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Jul 14, 2015
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
N=135 --> 59 | Trial primary completion date: Feb 2016 --> Aug 2015 Trial primary completion date: Aug 2015 --> Feb 2016
- | propranolol / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: STBETA: Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers (clinicaltrials.gov) - Jun 15, 2015
P2, N=15, Recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Aug 2015 --> Feb 2016 Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> May 2015 | Trial primary completion date: Nov 2016 --> Apr 2017
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial completion, Enrollment change, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - May 26, 2015
P1b, N=78, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> May 2015 | Trial primary completion date: Nov 2016 --> Apr 2017 Active, not recruiting --> Completed | N=120 --> 78
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 7, 2015
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=120 --> 78 N=50 --> 30
- || Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma (clinicaltrials.gov) - Apr 23, 2015
P2, N=86, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=50 --> 30 Trial primary completion date: Sep 2015 --> Sep 2016
- retaspimycin (IPI-504) / Infinity Pharma
Enrollment change, Metastases: Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma (clinicaltrials.gov) - Apr 14, 2015
P2, N=0, Withdrawn, Sponsor: Infinity Pharmaceuticals, Inc.
Trial primary completion date: Sep 2015 --> Sep 2016 N=40 --> 0
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial termination, Metastases: Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma (clinicaltrials.gov) - Feb 23, 2015
P1/2, N=29, Terminated, Sponsor: City of Hope Medical Center
N=40 --> 0 Completed --> Terminated; Drug availability issues
- alisertib (MLN8237) / Puma
Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Feb 12, 2015
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Drug availability issues Trial primary completion date: Mar 2015 --> Aug 2015
- alisertib (MLN8237) / Puma
Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Dec 17, 2014
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2015 --> Aug 2015 Trial primary completion date: Aug 2014 --> Mar 2015
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas (clinicaltrials.gov) - Dec 17, 2014
P1, N=5, Completed, Sponsor: Heidelberg University
Trial primary completion date: Aug 2014 --> Mar 2015 Recruiting --> Completed | N=24 --> 5 | Trial primary completion date: Nov 2012 --> Dec 2014
- |||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial primary completion date, Metastases: A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Dec 13, 2014
P3, N=141, Recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Recruiting --> Completed | N=24 --> 5 | Trial primary completion date: Nov 2012 --> Dec 2014 Trial primary completion date: Oct 2014 --> Mar 2018
- cyclophosphamide / Generic mfg.
Trial completion, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 12, 2014
P1, N=6, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Oct 2014 --> Mar 2018 Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg.
Trial primary completion date, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 23, 2014
P1, N=7, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Sep 2013
- | Januvia (sitagliptin) / Merck (MSD)
New P4 trial: Sitagliptin and Brown Adipose Tissue (clinicaltrials.gov) - Nov 19, 2014
P4, N=30, Not yet recruiting, Sponsor: IngridJazet
- cyclophosphamide / Generic mfg.
Enrollment closed, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 12, 2014
P1, N=7, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2014 --> Sep 2013 Recruiting --> Active, not recruiting
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Nov 7, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2014 --> Apr 2015
- | propranolol / Generic mfg.
Trial initiation date, Trial primary completion date: STBETA: Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers (clinicaltrials.gov) - Oct 30, 2014
P2, N=15, Not yet recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Nov 2014 --> Apr 2015 Initiation date: Mar 2014 --> Nov 2014 | Trial primary completion date: Mar 2016 --> Nov 2016
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment closed, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 10, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 2014 --> Nov 2014 | Trial primary completion date: Mar 2016 --> Nov 2016 Recruiting --> Active, not recruiting
- Xiaflex (collagenase clostridium histolyticum) / Asahi Kasei, SOBI, Endo
New P2 trial: Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma (clinicaltrials.gov) - Sep 28, 2014
P2, N=20, Recruiting, Sponsor: Gerut, Zachary, M.D.
- | Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Metastases: Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma (clinicaltrials.gov) - Sep 16, 2014
P2, N=38, Active, not recruiting, Sponsor: ACORN Research, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Trial completion, Metastases: A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer (clinicaltrials.gov) - Sep 6, 2014
P2, N=271, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- alisertib (MLN8237) / Puma
Trial suspension, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Aug 1, 2014
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Suspended
- cyclophosphamide / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (clinicaltrials.gov) - Jul 30, 2014
P1, N=12, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Suspended Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jul 2014 | Trial primary completion date: Jan 2016 --> Jun 2016
- | Trial completion, Trial primary completion date: An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation (clinicaltrials.gov) - Jul 24, 2014
P3, N=149, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jul 2014 | Trial primary completion date: Jan 2016 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Jul 2014
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Jul 21, 2014
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Jul 2014 Trial primary completion date: Aug 2014 --> Nov 2014
- |||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial primary completion date, Metastases: A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Jun 27, 2014
P3, N=582, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Aug 2014 --> Nov 2014 Trial primary completion date: Apr 2014 --> Dec 2014
- cyclophosphamide / Generic mfg.
Trial primary completion date, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 26, 2014
P1, N=7, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Apr 2014 --> Dec 2014 Trial primary completion date: Dec 2013 --> Dec 2014
- || Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma (clinicaltrials.gov) - Jun 8, 2014
P2, N=86, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Dec 2013 --> Dec 2014 Trial primary completion date: Sep 2014 --> Sep 2015